Fig. 2

Change in tumor size of evaluable patients treated with pembrolizumab in the non-adjuvant setting at doses of 200 mg Q3W (N = 713) (a), 2 mg/kg Q3W (N = 522) (b), 10 mg/kg Q3W (N = 399) (c), and 10 mg/kg Q2W (N = 95) (d). Figure includes tumor size change for all ADA evaluable patients. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent ADA positive; Q2W, every 2 weeks; Q3W, every 3 weeks; TE, treatment-emergent ADA positive